HRP20240166T1 - Postupak liječenja prader-willijevog sindroma - Google Patents
Postupak liječenja prader-willijevog sindroma Download PDFInfo
- Publication number
- HRP20240166T1 HRP20240166T1 HRP20240166TT HRP20240166T HRP20240166T1 HR P20240166 T1 HRP20240166 T1 HR P20240166T1 HR P20240166T T HRP20240166T T HR P20240166TT HR P20240166 T HRP20240166 T HR P20240166T HR P20240166 T1 HRP20240166 T1 HR P20240166T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- carbetocin
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 201000010769 Prader-Willi syndrome Diseases 0.000 title claims 2
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 claims 9
- 229960001118 carbetocin Drugs 0.000 claims 9
- 108700021293 carbetocin Proteins 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 3
- 239000007921 spray Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (13)
1. Pripravak koji sadrži karbetocin ili njegovu farmaceutski prihvatljivu sol za upotrebu u liječenju Prader-Willijevog sindroma, pri čemu liječenje uključuje intranazalno davanje dnevne doze od 5,76 mg do 28,8 mg karbetocina ili njegove farmaceutski prihvatljive soli.
2. Pripravak za upotrebu prema zahtjevu 1, naznačen time što se pripravak daje tri puta dnevno.
3. Pripravak za upotrebu prema zahtjevu 1, naznačen time što svaka primjena isporučuje 10 mg karbetocina ili njegove farmaceutski prihvatljive soli.
4. Pripravak za upotrebu prema zahtjevu 2, naznačen time što se svaka primjena provodi prije obroka.
5. Pripravak za upotrebu prema zahtjevu 1, naznačen time što liječenje uključuje davanje dnevne doze karbetocina ili njegove farmaceutski prihvatljive soli u količini od 10 mg do 28,8 mg.
6. Pripravak za upotrebu prema zahtjevu 1, naznačen time što liječenje uključuje davanje dnevne doze od 10 mg karbetocina ili njegove farmaceutski prihvatljive soli, ili davanje dnevne doze od 28,8 mg karbetocina ili njegove farmaceutski prihvatljive soli.
7. Pripravak za upotrebu prema zahtjevu 2, naznačen time što liječenje uključuje davanje dnevne doze od 28,8 mg karbetocina i pri čemu se pripravak primjenjuje kao intranazalni sprej.
8. Pripravak za upotrebu prema zahtjevu 2, naznačen time što liječenje uključuje davanje dnevne doze od 10 mg karbetocina ili njegove farmaceutski aktivne soli, i pri čemu se pripravak primjenjuje kao intranazalni sprej.
9. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time što se pripravak primjenjuje kao intranazalni sprej.
10. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time što pripravak sadrži karbetocin ili njegovu farmaceutski prihvatljivu sol otopljenu u vodenoj otopini.
11. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time što pripravak sadrži vodenu otopinu natrijevog klorida.
12. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time što vodena otopina sadrži 0,9 tež.% natrijevog klorida.
13. Pripravak za upotrebu prema zahtjevu 1, naznačen time što je pripravak u obliku praha.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052957P | 2014-09-19 | 2014-09-19 | |
| EP19216650.2A EP3666258B1 (en) | 2014-09-19 | 2015-09-14 | Method of treating prader-willi syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240166T1 true HRP20240166T1 (hr) | 2024-04-26 |
Family
ID=54238564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240166TT HRP20240166T1 (hr) | 2014-09-19 | 2015-09-14 | Postupak liječenja prader-willijevog sindroma |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10441627B2 (hr) |
| EP (2) | EP3666258B1 (hr) |
| JP (3) | JP6599447B2 (hr) |
| CN (2) | CN112773765A (hr) |
| CA (1) | CA2957224A1 (hr) |
| DK (1) | DK3666258T3 (hr) |
| ES (1) | ES2775425T3 (hr) |
| FI (1) | FI3666258T3 (hr) |
| HR (1) | HRP20240166T1 (hr) |
| LT (1) | LT3666258T (hr) |
| PL (1) | PL3666258T3 (hr) |
| PT (1) | PT3666258T (hr) |
| RS (1) | RS65144B1 (hr) |
| SI (1) | SI3666258T1 (hr) |
| WO (1) | WO2016044131A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3666258T (lt) | 2014-09-19 | 2024-01-10 | Ferring Bv | Praderio-vilio sindromo gydymo būdas |
| EP3665183A1 (en) | 2017-08-11 | 2020-06-17 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| WO2019032946A1 (en) | 2017-08-11 | 2019-02-14 | Ferring B.V. | PROCESS FOR PRODUCING OXYTOCIN |
| WO2019161179A1 (en) * | 2018-02-15 | 2019-08-22 | Ovid Therapeutics Inc. | Methods of treating developmental syndromes with pde10a inhibitors |
| US11207373B2 (en) * | 2018-09-20 | 2021-12-28 | Levo Therapeutics, Inc. | Agitation process for preparing a carbetocin drug product |
| WO2020061414A1 (en) * | 2018-09-20 | 2020-03-26 | Levo Therapeutics, Inc. | Stable intranasal formulations of carbetocin |
| CN116981468A (zh) * | 2020-12-18 | 2023-10-31 | 通用医疗公司 | 益生菌组合物以及使用其促进儿童生长和社交功能的方法 |
| TW202304498A (zh) | 2021-03-26 | 2023-02-01 | 法商Ｏｔ４Ｂ公司 | 吞嚥困難之治療 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7544662B2 (en) | 1993-06-17 | 2009-06-09 | Carle Development Foundation | Polypeptides useful for appetite suppression |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| US6894026B1 (en) | 2000-01-11 | 2005-05-17 | Atossa Healthcare, Inc. | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders |
| US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| AU2007354659B2 (en) * | 2007-06-07 | 2014-01-30 | Kyalin Bioscience, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| WO2009043453A2 (en) | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| WO2009033820A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| US20100190717A1 (en) | 2007-09-11 | 2010-07-29 | Dorian Bevec | Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
| ES2371521T3 (es) | 2007-09-11 | 2012-01-04 | Mondobiotech Laboratories Ag | Uso del péptido phpfhlfvy (inhibidor de renina) como agente terapéutico. |
| US8673841B2 (en) * | 2008-03-31 | 2014-03-18 | Ferring B.V. | Oxytocin analogues |
| EP2317845A4 (en) | 2008-07-18 | 2011-11-09 | Zafgen Inc | METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON |
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| ES2595251T3 (es) | 2010-05-25 | 2016-12-28 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Métodos y composición farmacéutica para el tratamiento de un trastorno alimentario con inicio temprano en un paciente |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| WO2012149472A2 (en) | 2011-04-27 | 2012-11-01 | Ignite Institute For Individualized Health | Methods, compositions, and kits for treating and preventing neurological conditions |
| PT2935312T (pt) * | 2012-12-21 | 2018-10-26 | Hoffmann La Roche | Péptidos enquanto agonistas da oxitocina |
| CN104936593B (zh) | 2013-01-17 | 2018-05-18 | 霍夫曼-拉罗奇有限公司 | 用于治疗cns疾病的催产素受体激动剂 |
| AU2015270723A1 (en) | 2014-06-03 | 2016-11-17 | F. Hoffmann-La Roche Ag | Peptides as oxytocin agonists |
| CR20160562A (es) | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
| SG11201700877PA (en) | 2014-08-07 | 2017-03-30 | Hoffmann La Roche | Processes for the preparation of oxytocin analogues |
| LT3666258T (lt) | 2014-09-19 | 2024-01-10 | Ferring Bv | Praderio-vilio sindromo gydymo būdas |
-
2015
- 2015-09-14 LT LTEP19216650.2T patent/LT3666258T/lt unknown
- 2015-09-14 DK DK19216650.2T patent/DK3666258T3/da active
- 2015-09-14 SI SI201531990T patent/SI3666258T1/sl unknown
- 2015-09-14 HR HRP20240166TT patent/HRP20240166T1/hr unknown
- 2015-09-14 PL PL19216650.2T patent/PL3666258T3/pl unknown
- 2015-09-14 EP EP19216650.2A patent/EP3666258B1/en active Active
- 2015-09-14 WO PCT/US2015/049911 patent/WO2016044131A1/en active Application Filing
- 2015-09-14 JP JP2017515228A patent/JP6599447B2/ja active Active
- 2015-09-14 US US15/510,781 patent/US10441627B2/en active Active
- 2015-09-14 EP EP15772107.7A patent/EP3193907B1/en active Active
- 2015-09-14 FI FIEP19216650.2T patent/FI3666258T3/fi active
- 2015-09-14 CN CN202110278199.4A patent/CN112773765A/zh active Pending
- 2015-09-14 CA CA2957224A patent/CA2957224A1/en active Pending
- 2015-09-14 ES ES15772107T patent/ES2775425T3/es active Active
- 2015-09-14 RS RS20240134A patent/RS65144B1/sr unknown
- 2015-09-14 PT PT192166502T patent/PT3666258T/pt unknown
- 2015-09-14 CN CN201580049147.2A patent/CN106714819A/zh active Pending
-
2019
- 2019-10-02 JP JP2019181930A patent/JP6921154B2/ja active Active
- 2019-10-03 US US16/592,632 patent/US20200129584A1/en not_active Abandoned
-
2021
- 2021-03-15 JP JP2021041334A patent/JP2021098745A/ja active Pending
-
2022
- 2022-11-18 US US18/057,065 patent/US20240082344A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106714819A (zh) | 2017-05-24 |
| FI3666258T3 (fi) | 2024-02-09 |
| JP2021098745A (ja) | 2021-07-01 |
| PT3666258T (pt) | 2024-02-01 |
| ES2775425T3 (es) | 2020-07-27 |
| US20200129584A1 (en) | 2020-04-30 |
| EP3666258A1 (en) | 2020-06-17 |
| SI3666258T1 (sl) | 2024-04-30 |
| US20170326200A1 (en) | 2017-11-16 |
| CN112773765A (zh) | 2021-05-11 |
| RS65144B1 (sr) | 2024-02-29 |
| EP3666258B1 (en) | 2023-11-15 |
| EP3193907B1 (en) | 2020-01-01 |
| JP2017532316A (ja) | 2017-11-02 |
| JP6599447B2 (ja) | 2019-10-30 |
| US20240082344A1 (en) | 2024-03-14 |
| LT3666258T (lt) | 2024-01-10 |
| JP2020019790A (ja) | 2020-02-06 |
| EP3193907A1 (en) | 2017-07-26 |
| CA2957224A1 (en) | 2016-03-24 |
| WO2016044131A1 (en) | 2016-03-24 |
| DK3666258T3 (da) | 2024-02-05 |
| US10441627B2 (en) | 2019-10-15 |
| JP6921154B2 (ja) | 2021-08-18 |
| PL3666258T3 (pl) | 2024-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| HRP20220759T1 (hr) | Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti | |
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| MY196072A (en) | Liquid Inhalation Formulation Comprising RPL554 | |
| MX2021013139A (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| AU2017312811A8 (en) | Liquid naloxone spray | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| EA201992382A3 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
| PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| MY196333A (en) | Intranasal Composition Comprising Betahistine | |
| MX2018011293A (es) | Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. | |
| MX2015012666A (es) | Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo. | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| MX2015006356A (es) | Formulacion de capsula de acido 5-aminosalicilico. | |
| MX2020006900A (es) | Composición de ketamina en polvo seco para usarse en el tratamiento de depresión por medio de administración pulmonar. | |
| UA111123C2 (uk) | Застосування комбінованого терапевтичного засобу для лікування риніту | |
| MX2016009475A (es) | Composiciones efectivas contra la conjuntivitis viral. | |
| PH12020550597A1 (en) | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt | |
| GR1008380B (el) | Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου | |
| HRP20192028T1 (hr) | Arginin, namijenjen upotrebi u liječenju i/ili sprječavanju osteoartritisa |